Proceeds from the financing will enable Bactolife to advance its most mature projects towards commercial launch and strengthen the technology platform and upscaling capabilities. By doing so, the company aims at retaining its first mover advantage to transform human and animal health with target specific Binding Proteins.

The company intends to use the funds to expand R&D and clinical development efforts of its brain energetics products based on ketone bodies. KetoSwiss’ flagship product MigraKet a dietary-preventive therapy for migraine and related diseases that are characterized by metabolic dysfunction.

The financing will help advance commercial operations driving adoption of the ECGenius System, the company’s innovative EP recording technology, and support the continued development of artificial intelligence-powered analytic modules to provide electrophysiologists with unprecedented levels of automated analysis during cardiac ablation procedures. This includes expansion of the company’s sales team and U.S. presence, and further …